Diazoxide Suppression Test P&F Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

January 31, 2026

Conditions
Insulin ResistanceHyperinsulinemiaObesity
Interventions
DRUG

Diazoxide, 3 mg/kg per dose

Insulin anti-secretagogue taken for 8 doses over 4 days

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

University of Pisa

OTHER

lead

Columbia University

OTHER